The Supreme Court could say today whether it will review a case involving a "pay for delay"...
Friday, December 7, 2012, 4:41 AM ETThe Supreme Court could say today whether it will review a case involving a "pay for delay" agreement in which a pharmaceutical company pays generic rivals tens of millions of dollars to hold off from launching copycat versions of medicines. The FTC says the practice costs customers $3.5B a year, while drug firms argue that it protects innovation. Companies that could be affected include Abbott (ABT), Watson (WPI), Merck (MRK), Bristol-Myers Squibb (BMY) and Teva (TEVA).
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles